AU Patent

AU2014201239B2 — Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate

Assigned to AstraZeneca AB · Expires 2016-03-10 · 10y expired

What this patent protects

The present invention provides for a pharmaceutical formulation comprising dapagliflozin propylene glycol hydrate and a pharmaceutical acceptable carrier. Uses of the formulation in the manufacture of a medicament for treating or delaying the progression of Type I or Type 11 diab…

USPTO Abstract

The present invention provides for a pharmaceutical formulation comprising dapagliflozin propylene glycol hydrate and a pharmaceutical acceptable carrier. Uses of the formulation in the manufacture of a medicament for treating or delaying the progression of Type I or Type 11 diabetes and related conditions are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014201239B2
Jurisdiction
AU
Classification
—
Expires
2016-03-10
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.